Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

".cf_pushbutton_activate").live("mouseover", function (){ //Omniture Link Tracking Code /*var s=s_gi(s_account); s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.prop16='CrowdFactory_Share'; s.tl(this,'o', 'CrowdFactory_Share');*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106713988';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106713988';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

Conference Call on Thursday, November 4, 2010 at 4:30 p.m. Eastern Time

BOTHELL, WA, and VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three and nine months ended September 30, 2010 and provided an update on the business, the recent financing and anticipated use of proceeds to advance the product pipeline.

"The public offering in October was a transformative event for us," said Scott Cormack, president and chief executive officer of OncoGenex. "The $46.7 million in estimated net proceed
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. OncoGenex Reports Second Quarter Financial Results
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... , ... 13 Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced ... CellerateRX in Mexico and has identified its first distributor ... the Activated Collagen wound care product and were impressed with its ...
... , , ... bio-based chemical companies, including cellulosic ethanol pioneer Verenium Corporation ...  Qteros, Inc., a leading developer of second-generation technology solutions ... platform, announced today that John McCarthy has joined ...
... Mass. , Jan. 13 Toxikon, a successful, ... in the Greater Boston area, announces that ... the continued growth of the preclinical and clinical bioanalytical services ... to the organization from his prior roles in method development, ...
Cached Biology Technology:Wound Management Technologies, Inc. Rapidly Expands Its International Presence 2Wound Management Technologies, Inc. Rapidly Expands Its International Presence 3Wound Management Technologies, Inc. Rapidly Expands Its International Presence 4Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer 2Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer 3
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... PORTLAND, Ore. New research in mice indicates that babies ... during pregnancy have a higher fat mass and smaller livers ... at Oregon Health & Science University Doernbecher Children,s Hospital. ... who switch to a low-fat diet during pregnancy considerably reduce ...
... A team of researchers from the Georgia Institute of ... of Florida to study how the diversity of seaweed-eating fish ... Sept. 13, may provide new information to help scientists protect ... Led by Mark Hay, a Georgia Tech professor of biology, ...
... -- Pharmaceutical poisoning remains a common childhood injury, despite years ... packaging. Over half a million children are exposed to ... published in The Journal of Pediatrics attempts to ... reducing the number of childhood injuries due to pharmaceutical poisoning. ...
Cached Biology News:Moms who eat high-fat diet before, during pregnancy 'program' babies to be fat, at risk 2Study in underwater laboratory may help manage seaweed-eating fish that protect coral 2Study in underwater laboratory may help manage seaweed-eating fish that protect coral 3Study finds an increase of children accidentally poisoned with pharmaceuticals 2
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
... EPS 3501 XL Power Supply, 1. 3500 ... constant current, constant power, and linear voltage ... to focused equilibrium in IPG strips quickly ... compensate for variations in gel thickness, sample ...
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Biology Products: